VanEck Pharmaceutical ETF (PPH)
| Assets | $1.19B |
| Expense Ratio | 0.36% |
| PE Ratio | 19.10 |
| Shares Out | 11.84M |
| Dividend (ttm) | $1.94 |
| Dividend Yield | 1.94% |
| Ex-Dividend Date | Oct 1, 2025 |
| Payout Ratio | 37.11% |
| 1-Year Return | +10.56% |
| Volume | 162,221 |
| Open | 100.43 |
| Previous Close | 99.85 |
| Day's Range | 99.48 - 100.62 |
| 52-Week Low | 77.67 |
| 52-Week High | 103.56 |
| Beta | 0.48 |
| Holdings | 25 |
| Inception Date | Feb 1, 2000 |
About PPH
Fund Home PageThe VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is issued by VanEck.
Top 10 Holdings
74.79% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 24.21% |
| Novartis AG ADR | NVSN.MX | 9.10% |
| Merck & Co., Inc. | MRK | 8.13% |
| Novo Nordisk A/S | NVO | 5.95% |
| GSK plc | GSK | 4.81% |
| Johnson & Johnson | JNJ | 4.65% |
| Pfizer Inc. | PFE | 4.60% |
| McKesson Corporation | MCK | 4.54% |
| AstraZeneca PLC | AZN | 4.47% |
| AbbVie Inc. | ABBV | 4.33% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Oct 1, 2025 | $0.3931 | Oct 6, 2025 |
| Jul 1, 2025 | $0.6069 | Jul 7, 2025 |
| Apr 1, 2025 | $0.5245 | Apr 4, 2025 |
| Dec 27, 2024 | $0.411 | Dec 30, 2024 |
| Oct 1, 2024 | $0.409 | Oct 4, 2024 |
| Jul 1, 2024 | $0.3558 | Jul 5, 2024 |
News
Britain will spend more on new medicines in exchange for avoiding tariffs on U.K. pharmaceutical exports to the U.S.
The move marks a victory for the Trump administration's campaign to get other countries to pay more for drugs.
Ozempic—and 14 other popular prescription drugs—will cost less for Medicare after the U.S. government negotiated lower prices
The price cuts will save Medicare billions of dollars in prescription-drug spending.
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discoun...
Top Pharmaceutical Companies Shaping the Future of Healthcare
Pharma's strong pipelines, reduced policy risks, and demand growth drive renewed investor interest. PPH offers targeted access to top innovators like Eli Lilly and Merck.
Drug Stocks Just Had Their Best Week in 2 Decades. Should You Invest?
Pharmaceutical stocks are having a moment. The S&P 500 Pharmaceuticals Index recently rose 11% during five trading days, its best weekly gain since 2022.
Final Trade: JCI, PPH, TOL, IBM
The final trades of the day with the Fast Money traders.
Drug Tariffs Are a Sideshow. Trump's Next Move Could Hit Pharma Harder.
What unnerves investors is a lack of clarity on drug pricing.
Big Pharma Unfazed by Trump Tariffs, But Small Biotechs Face Vulnerability
Drugmakers have been bracing for levies and sought to get ahead of them with pledges to invest billions more on domestic manufacturing.
Trump announces 100% tariffs on pharmaceutical drugs, beginning October 1
President Donald Trump said Thursday that he will put import taxes of 100% on pharmaceutical drugs, 50% on kitchen cabinets and bathroom vanities, 30% on upholstered furniture and 25% on heavy trucks ...
Pharma stocks gain, as Trump's tariff move actually could be a win for the sector
Pharmaceutical stocks mostly gained Friday, as traders appeared to shrug off or even cheer President Donald Trump's rollout of a new tariff plan for drugmakers.
PPH: Excellent Pharmaceutical ETF, But Bad Timing To Invest
VanEck Pharmaceutical ETF offers focused exposure to large-cap pharmaceutical companies, benefiting from strong long-term demographic and innovation trends. PPH's high concentration in top holdings an...
PPH: Global Pharma Stocks Continue To Face Headwinds, Tariffs Front And Center
I maintain a hold rating on PPH due to attractive valuation but weak technical momentum and underperformance versus the S&P 500. Eli Lilly and Johnson & Johnson, PPH's largest holdings, are facing uni...
Are Your Health Care ETFs Safe? Trump's New Policies May Trigger Shockwaves Across Pharma Stocks
As the drug industry is in the middle of a growing policy maelstrom in Washington, D.C., investors are closely watching pharmaceutical ETFs to measure market sentiment and ride out the emerging volati...
PPH: Will Overcome Tariffs, But Competitor Funds Look Stronger
VanEck Pharmaceutical ETF holds a mixed outlook due to high fees and tariff risks, warranting a hold rating despite strong top holdings. PPH's top holdings like Eli Lilly and Johnson & Johnson have di...
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Final Trade: MSTR, PPH, TLT, MCD
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Pharma Stocks Losing Ground After A Remarkable Rally, Downgrading PPH
The VanEck Pharmaceutical ETF has shown strong performance but faces near-term downside risks, prompting a rating downgrade from buy to hold. PPH's valuation has increased significantly, with a high p...
PPH: A Strong Fund To Play Big Pharma
The Health Care sector bullish due to AI technology. VanEck Pharmaceutical ETF offers exposure to leading pharmaceutical companies. The defensive nature of the pharmaceutical sector makes it somewhat ...
PPH: Buy The Pullback In This Big Pharma ETF For Long-Term Total Returns
VanEck Pharmaceutical ETF is a popular option for investors looking for exposure to leading pharmaceutical companies. The ETF has been in an uptrend since late last year and is currently trading at a ...
PPH: Ignore The Election Scare, Buy Pharma And Healthcare
Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms...
Healthcare In 2024: Navigating The Biopharma Bull Run
The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to...
Pharma Is Out of Favor. 5 Drug Stocks With Room to Grow.
Despite Eli Lilly's monster 66.8% gain on the year because of weight-loss drugs, the S&P 500 Pharmaceuticals index is down 2.3%.